Advice
in the absence of a submission from the holder of the marketing authorisation
denosumab (Xgeva®) is not recommended for use within NHS Scotland.
Indication under review: Adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice49KB (PDF)
Medicine details
- Medicine name:
- denosumab (Xgeva)
- SMC ID:
- 1119/15
- Indication:
- Adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 December 2015